Loading stock data…
Adlai Nortye Ltd. (ANL)
$15.51+0.50 (+3.33%)
After Hours$15.51+0.00 (+0.00%)· Last close Sep 8
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adlai Nortye Ltd. in the Healthcare sector is trading at $15.51 with a market capitalization of $725M. Wall Street consensus targets $24.25 (4 analysts), implying a +56.4% move over the next 12 months. The stock is currently near its 52-week high of $17.25, remaining 71.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +56.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | -$16.86M |
| Net Income | — | — | — | — | -$63.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/ch...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$725.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
942.30%
Volume
Today's trading volume
404,955
Recent News
These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
Ask any old-school market investor and he’ll tell you that the cliché is true, and ‘past performance cannot guarantee future returns.’ If that were true without exception, then growth investing would not be a viable option – but we all know that investors love to buy into stocks that have shown enormous growth in recent months. The ‘monster growth’ stocks are popular because investing into them is successful. The key is understanding the smart middle way, and treating stocks as individuals, with
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?
The consensus price target hints at an 81.8% upside potential for Adlai Nortye Ltd. Sponsored ADR (ANL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.